Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7494187rdf:typepubmed:Citationlld:pubmed
pubmed-article:7494187lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:7494187lifeskim:mentionsumls-concept:C0025914lld:lifeskim
pubmed-article:7494187lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:7494187lifeskim:mentionsumls-concept:C0929301lld:lifeskim
pubmed-article:7494187lifeskim:mentionsumls-concept:C0006141lld:lifeskim
pubmed-article:7494187lifeskim:mentionsumls-concept:C0011209lld:lifeskim
pubmed-article:7494187lifeskim:mentionsumls-concept:C1450054lld:lifeskim
pubmed-article:7494187lifeskim:mentionsumls-concept:C0071443lld:lifeskim
pubmed-article:7494187lifeskim:mentionsumls-concept:C0384438lld:lifeskim
pubmed-article:7494187pubmed:issue5lld:pubmed
pubmed-article:7494187pubmed:dateCreated1996-1-11lld:pubmed
pubmed-article:7494187pubmed:abstractTextHexadecafluoro zinc phthalocyanine (ZnPcF16), a second generation sensitizer for the photodynamic therapy of cancer, was incorporated in three vehicles: poly(D,L-lactic acid) (PLA) nanoparticles, polyethylene glycol (PEG)-coated nanoparticles and a Cremophor EL (CRM) oil-water emulsion. Nanoparticles were prepared by the salting-out procedure. Biodistribution of the dye was assessed by fluorescence in EMT-6 mammary tumour bearing mice after intravenous injection of 1 mumol kg-1 ZnPcF16. Plain nanoparticles were rapidly retained by the reticuloendothelial system (RES) as reflected by the low area under the blood concentration-time curve (AUC0-168, 57 micrograms h g-1). Little tumour uptake of the dye was observed with this formulation. In contrast, PEG-coated nanoparticles displayed a reduced RES uptake, leading to significantly higher blood levels over an extended period (t1/2 30 h; AUC 0-168 227 micrograms h g-1) and enhanced tumour uptake. At 48 h post injection, tumour to skin and tumour to muscle concentration ratios reached 3.5 and 10.8, respectively. Blood levels of ZnPcF16 after administration as a CRM emulsion decreased faster than with PEG-coated nanoparticles (t1/2 12 h), but since no early liver uptake was observed, the AUC0-168 and the tumour uptake were only slightly lower. However, with the CRM formulation, a late liver uptake was observed, reaching 51% of the injected dose after 7 days.lld:pubmed
pubmed-article:7494187pubmed:languageenglld:pubmed
pubmed-article:7494187pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7494187pubmed:citationSubsetIMlld:pubmed
pubmed-article:7494187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7494187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7494187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7494187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7494187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7494187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7494187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7494187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7494187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7494187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7494187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7494187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7494187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7494187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7494187pubmed:statusMEDLINElld:pubmed
pubmed-article:7494187pubmed:monthMaylld:pubmed
pubmed-article:7494187pubmed:issn0022-3573lld:pubmed
pubmed-article:7494187pubmed:authorpubmed-author:RousseauJJlld:pubmed
pubmed-article:7494187pubmed:authorpubmed-author:GurnyRRlld:pubmed
pubmed-article:7494187pubmed:authorpubmed-author:BoyleR WRWlld:pubmed
pubmed-article:7494187pubmed:authorpubmed-author:Van LierJ EJElld:pubmed
pubmed-article:7494187pubmed:authorpubmed-author:BenrezzakOOlld:pubmed
pubmed-article:7494187pubmed:authorpubmed-author:LerouxJ CJClld:pubmed
pubmed-article:7494187pubmed:authorpubmed-author:BrasseurNNlld:pubmed
pubmed-article:7494187pubmed:authorpubmed-author:AllémannEElld:pubmed
pubmed-article:7494187pubmed:authorpubmed-author:KudrevichS...lld:pubmed
pubmed-article:7494187pubmed:issnTypePrintlld:pubmed
pubmed-article:7494187pubmed:volume47lld:pubmed
pubmed-article:7494187pubmed:ownerNLMlld:pubmed
pubmed-article:7494187pubmed:authorsCompleteYlld:pubmed
pubmed-article:7494187pubmed:pagination382-7lld:pubmed
pubmed-article:7494187pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:meshHeadingpubmed-meshheading:7494187-...lld:pubmed
pubmed-article:7494187pubmed:year1995lld:pubmed
pubmed-article:7494187pubmed:articleTitlePEG-coated poly(lactic acid) nanoparticles for the delivery of hexadecafluoro zinc phthalocyanine to EMT-6 mouse mammary tumours.lld:pubmed
pubmed-article:7494187pubmed:affiliationMRC Group in the Radiation Sciences, Faculty of Medicine, University of Sherbrooke, Québec, Canada.lld:pubmed
pubmed-article:7494187pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7494187pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7494187lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7494187lld:pubmed